Reasearch of anticancer peptide from Meretrix meretrix Linnaeus by 冷波
学校编码：10384                               分类号：         密级：       




博 士 学 位 论 文 
 
文蛤抗癌活性多肽的研究 
Reasearch of anticancer peptide from Meretrix 
meretrix Linnaeus 
冷 波 
指 导 教 师：     陈清西    教授  
专 业 名 称：生物化学与分子生物学 
论文提交日期： 2007 年 5 月 29 日 
论文答辩时间： 2007 年 6 月 30 日 
学位授予日期： 2007 年 月  日 
 
答辩委员会主席：  刘 波    
评   阅   人：            
                                    
 






















































  1、保密（ ），在   年解密后适用本授权书。 




作者签名：      日期：2007 年 7 月 3 日 
导师签名：      日期：2007 年 7 月 3 日 
 
 























1.1.2 癌症的治疗方法…………….. …………………………………......…………..14 
1.1.2.1 手术治疗……………….………………………………………....…………....14 
1.1.2.2 放射治疗……………….………………………………………....…………....14 
1.1.2.3 化学药物治疗…………….. …………………………………....………….....14 
1.1.2.3 生物治疗……………….………………………………………....…………....15 
1.2 海洋抗癌生物活性物质研究…………………………………….....………....…17 
1.2.1 肽 类……………….……………………………………………………….......18 
1.2.2 大环内酯…………….…………………………………………………………...20 






































2.2.3.5 MP1 对体外培养人肝癌 SMMC-7721 细胞生长曲线的影响…….……........36 
2.2.3.6 MP1 对体外培养人肝癌 SMMC-7721 细胞形态及显微结构的影响...……..37 
2.2.3.7 MP1 对体外培养人肝癌 SMMC-7721 超微结构的影响…………………….37 
2.2.3.8 MP1 对体外培养人肝癌 SMMC-7721 细胞周期的影响………..………….37 
2.2.4 MP1 对体外培养人肝癌 SMMC-7721 蛋白质组学的影响…………………….37 
2.2.4.1 样品处理………………………..…….…………………..………....……….37 
2.2.4.2 第一向等电聚焦胶电泳（IEF）..…….………………….. ……………......38 
2.2.4.3 第二向 SDS-PAGE 电泳…………….….…………………………………......38 
2.2.4.4 银染色…………….….…………………………….…. …......……….....…..38 
2.2.4.5 考马斯亮蓝 G-250 染色…………….….……………………………………38 
2.2.4.6 扫描和图象处理…………….….…………………………….……….…......39 
2.2.4.7 蛋白质胶内酶切…………….….…………………………….…. ……….....39 
2.2.4.8 质谱结果检索…………….….…………………………….…. ………….....39 
3、 实验结果与分析……………………….….…………………………………….40 
3.1 文蛤抗癌活性物质的分离纯化…..…………………………….... …………....40 
3.1.1 文蛤抗癌活性物质分离纯化条件的优化…..………………………….....…..40 
3.1.2 文蛤抗癌活性物质的纯度鉴定…..………………………………………........42 
3.2  文蛤抗癌活性多肽对癌细胞的细胞生物学效应…………………………....42 















3.2.2 文蛤抗癌活性多肽对肝癌 SMMC-7721 细胞生长曲线的影响……………..45 
3.2.3 文蛤多肽对肝癌 SMMC-7721 细胞形态和显微结构变化的影响.....…….…45 
3.2.4 文蛤抗癌活性多肽对肝癌 SMMC-7721 细胞超微结构变化的影响………..48 
3.2.5 文蛤抗癌活性多肽对肝癌细胞 SMMC-7721 细胞周期的影响……………..50 
3.3 蛋白质组学技术研究文蛤抗癌活性多肽对人肝癌细胞 SMMC-7721 
蛋白表达的影响……….…………………………………..…………………...52 








4.2.4 角蛋白 8……….……………………………………………………………….65 
4.2.5 核纤层蛋白……….……………………………………………………………68 
4.2.6 Protein disulfide isomerase……….……………………………………………72 
4.2.7 锌指蛋白……….………………………………………………………………74 




























1.1 Danger and therapy method of cancer………………………………………....13 
1.1.1 Danger of cancer……………….…………………………………………….....13 
1.1.2 Therapy method of cancer…………….. ……………………………………….14 
1.1.2.1 Surgery therapy method………….…………………………………………...14 
1.1.2.2 Radiation therapy method……….……………………………………………14 
1.1.2.3 Chemical remedy therapy method….. ……………………………………….14 
1.1.2.3 Biological therapy method……….………………………………......……….15 
1.2 Research of anticancer substance from natural marine organism…... ……...17 
1.2.1 Active peptide……………….…………………………………………………..18 
1.2.2 Macrocyclic lactone………….………………………………………………….20 
1.2.3 Polysaccharide and its derivates………………………………………………...22 
1.2.4 Alkaloid……………….……………………………………………... ……..….23 
1.2.5 Terpene……………….…………………………………………………....…....24 
1.2.6 Others……………….…………………………………………………......…....24 
1.3 Research of Mercenia and its physiological active………………………….....26 
1.3.1 Anticancer function…….…………………………………………………...... ..27 
1.3.2 Increase of immune ability…….…………………………………………….….27 
1.3.3 Depressing of blood sugar and lipid.……………………………………………28 
1.3.4 Others…….……………………………………………......………......…......…28 
1.4 The meaning of our research……………………………………………..…... ..29 
2. Material and methods………………….……………………………..….……....31 
2.1Material， reagent and apparatus……………………………………..…...….31 















2.1.2 Cancer cells………………….………………………..….……………......…....31 
2.1.3 Experiment apparatus………………….………………………..………………31 
2.1.4 Reagent………………….………………………………………………………32 
2.2 Experiment methods…………………..…….………………….. .. ……....….....34 
2.2.1Purification of anticancer peptide from Mercenia………….…………………….34 
2.2.2 Titer of protein……………………………………………………………….......34 
2.2.3Culture of tumour cells and determine of its cell biological effect…………....... 35 
2.2.3.1 Revivification of cells………………………………………………………….35 
2.2.3.2 Generation……………………………………...………….... ......………….....35 
2.2.3.3 Compare of concentration effect of anticancer peptide from 
 Mercenia on several cancer cells in vitro……………………………………. 35 
2.2.3.4 H.E. dyeing……………………………………...………….... ……......…..….36 
2.2.3.5 Effect of anticancer peptide from Mercenia on growth curve of  
heptacarcinoma SMMC-7721 cells in vitro…………………………………..36 
2.2.3.6 Effect of anticancer peptide from Mercenia on morphology and  
microstructure of heptacarcinoma SMMC-7721 cells in vitro………….…….37 
2.2.3.7 Effect of anticancer peptide from Mercenia on ultrastructure  
of heptacarcinoma SMMC-7721 cells in vitro………………......…......…......37 
2.2.3.8 Effect of anticancer peptide from Mercenia on cell cycle  
of heptacarcinoma SMMC-7721 cells in vitro……………………………………..….37 
2.2.4 Effect of anticancer peptide from Mercenia on proteomic  
of heptacarcinoma SMMC-7721 cells in vitro………………………………………...37 
2.2.4.1 Sample preparation…………………………………………...…...………..….37 
2.2.4.2 First dimension: IEF……………………………………………...………...….38 
2.2.4.3 Second dimension: SDS-PAGE……………………………………………….38 
2.2.4.4 Silver-staining……………………………………...………………...…...…...38 
2.2.4.5 Coomassie brilliant blue G-250 staining………………………………………38 
2.2.4.6 Scan and computer assisted 2-D image analysis……………………………...39 
2.2.4.7 Protein digest in gel…………….….…………………………….…. ………..39 















3. Results and analysis………………….….…………………………….…………......40 
3.1 Purification of anti-cancer peptide from Mercenia…..........…......…......…………40 
3.1.1 Optimization of purification of anticancer peptide from Mencenia…………….....40 
3.1.2 Purity determine of anticancer peptide from Mercenia…………….….………......42 
3.2 Cell biological effect MP1 on several cancer cells…………….….………....…... 42 
3.2.1 Compare of inhibitory effects of MP1 on several cancer  
cells by MTT method…………………..…….…………………..……......…....... ..42 
3.2.2 Effect of MP1 on growth curve of hepatocarcinoma SMMC-7721 cells……….....45 
3.2.3 Effect of MP1 on morphology and microstructure of  
hepatocarcinoma SMMC-7721 cells……………………….…………………….....45 
3.2.4 Effect of MP1 on ultrastructure of hepatocarcinoma SMMC-7721 cells……….....48 
3.2.5 Effect of MP1 on cell-cycle of hepatocarcinoma SMMC-7721 cells......………….50 
3.3 Research of effect of MP1 on expressed proteins of  
hepatocarcinoma  SMMC-7721 cells in vitro by proteomics method………….52 
3.3.1 Change of expressed proteins of SMMC-7721 cells  
before and after treated by MP1…………………..…….…………………..…….....52 
3.3.2 Identification of proteins by searching 2-D database…………………………....... 54 
4. Discussion…….…………………………………..……………………….....……….....59 
4.1 Purification and cell biological effects of MP1 from Mercenia……………….….59 
4.2 Ananlysis of differentially expressed proteins of SMMC-7721  
cells before and after treated by MP1……………………….…………………….60 
4.2.1 α-enolase…………………..…….…………………..……......…………......…......61 
4.2.2 Aldose reductase…………………..…….…………………..……………......…....62 
4.2.3 Phosphoglycerate mutase…………………..…….…………………………..…….64 
4.2.4 Keratin 8…………………..…….…………………..……......…………......…......65 
4.2.5 lamins…………………..…….…………………..……......…………......…......…68 
4.2.6 Protein disulfide isomerase……………………………………………………..…72 
4.2.7 Zinic finger protein…………………..…….…………………………..……….....74 














































































下调，40 个表达上调。对其中部分差异较明显的点进行了鉴定， 终鉴定出 11 种差异























Cancer is one of the most dangerous diseases of human being. In nowadays, it has the 
highest mortality in place of blood vessel disease in china and is worthy of the name of “the 
first killer”. Many researches were reported that the anticancer component from natural 
organism could combine with special regulation target during the course of growth, develop 
and malignance of cancer. Screening out those active substances have been the hotspot in the 
work of finding new effective anticancer medicament, and it is also one of the most important 
aspects in research of biomedicine in china now. Traditional anticancer medicines have many 
disadvantages such as heavy side-effect and toxicity, nonspeciality, facility of antigen and so 
on. Compared with them, the anticancer peptides from natural organism have many 
excellences, including multifunction, sensitivity, stability, lower side-effect and lower toxicity, 
and it has no antigen character also. Furthermore, the synthesis of the anticancer peptide is 
ease because of its simple structure. Meretrix Meretrix Linnaeus are smooth-shelled marine 
mussels.They are delicious and have medicinal properties. Many researchers have reported 
that extraction from Mercenenia had inhibitory effect on cancer of lung, gastrintestine, liver 
and hypothyroid, and there also were plenty of researches about its function of depressing 
blood sugar and lipid. It was also reported that extraction from Mercenenia had resistance to 
decrepitude, oxidation and nucleus mutation. Furthermore, some people reported that there 
was powerful immunocompetence in extraction from Mercenenia. Now more and more 
researchers are intresting in study of anticancer active of extract from Meretrix meretrix 
Linnaeus. 
In this study, in order to purify the active component from Mercenenia, the purification 
protocol was optimized at first. Then, on this base, we used a series of methods including 
fragmentation, organic precipitation, column chromatogram and HPLC. Finally, the 
anticancer peptide was obtained. The peptide was determined to be single band on the gel of 
PAGE, and we named it as MP1.  
The research of cell biology indicated that MP1 could strongly inhibited 
hepatocarcinoma cells SMMC-7721, gastrintestinal tumour cells SGC-7901 and BGC-823 in 
low concentration, and the IC50 to those cells were all lower than 5 µg/mL. 
The inhibitory effects of MP1 on the SMMC-7721 cells, including its effects on their 
proliferation, microstructure, ultrastructure and cell-cycle, were first been investigated. The 
cell proliferation and the inhibition rates were determined by cell counting methods and MTT 
methods, respectively. The microstructures and ultrastructure of the cells were observed by 
scan electron microscope and transmission electron microscope, respectively. The cell cycle 
was analyzed by flow cytometry. It was found that the SMMC-7721 cells, after they were 
treated by 5.0 μg/mL of MP1, grew slower than the control, their doubling time were 
postponed and the inhibitory rate on the cell growth was determined to be 89.4%. In the mean 















significantly decreased and what in the S phase was increased markedly. The apoptosis rate 
was up to 9.29%. Electron microscope results revealed that the cells’ morphological, 
microstructural and ultrastructural changes exhibited obviousl apoptotsis properties. These 
results indicated that MP1 could effectively inhibit the proliferation of the human 
hepatocarcinoma cell line SMMC-7721 in vitro and might act as an apoptosis inducer in its 
antitumor effects via inducing morphological changes and cell cycle arrest. 
Proteomics technology was used to study the potential molecular mechanism of 
inhibitory effects of MP1 on the SMMC-7721. 2-D patterns were obtained and analysised by 
using 2-D software-melanie 4. Proteins were digested by enzyme trypsin in gel and 
MALDI-TOF analysis were carried out in the proper order. Finally, we identified differential 
proteins expressed in the gels by searching protein database. 
About 136 differential expressed proteins were found on two patterns. One was the 
control cells proteins pattern, the other was that of cells treated by MP1. There were 96 
down-regulated proteins and 40 up-regulated proteins in two pieces of patterns. We choosed 
some proteins which changed markedly and identified them by MS. 11 proteins were 
identified successfully, 6 down-regulated proteins and 5 up-regulated proteins. These proteins 
included cyskeletal protein, zinc finger protein, metabolism-related enzyme, transcription 
regulation factors and so on. Finally, we discussed the fuctions of some of these proteins and 
attempted to come up with the hypotheses to explain the potential molecular mechanism of 
inhibitory effects of MP1 on the SMMC-7721. 
     























恶性肿瘤者达 690 万人，新发病率约为 870 万例；1999 年患病例为 3710 万例，数字还在
逐年增加。据世界卫生组织 1997 年年度报告，1996 年全球应癌症癌症死亡的有 630 万人，
约占总死亡率的 12%，其中近 60%死于肺癌、胃癌、乳腺癌、结肠直肠癌、口腔癌、肝癌、
宫颈癌及食管癌，是仅次于心血管疾病的第二大死因。自 1996 年以来，全球每年新确诊的
肿瘤病人约在 1030 万以上，到 1999 年底，全球肿瘤病人总数已逾 4000 万人。在美国，
每三十秒就有一个人被诊断为癌症，每五十五秒就有一个人死于癌症。为此，世
界卫生组织把每年的 2 月 4 日定为世界抗癌日，以联合全球共同攻克癌症[2]。我
国的肿瘤发病率同样十分惊人，根据卫生部 1973～1975 年及 1990～1992 年两次全国范围
的死因调查结果显示，到二十世纪九十年代，我国肿瘤发病率已上升为 0.127%；近 20 年
的恶性肿瘤在死因中的构成比，已由 12.6%升至 17.9%，我国台湾省的更高，每五个死亡
人口就有一人死于癌症，癌症死亡率占总死亡率 20%；近年来国内每年新增肿瘤病
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